## NEM: Newmont Corporation - XLB: Basic Materials

### Executive Summary

No thesis match: MRS_10 -1.5% below STRENGTH zone (3.0-6.0%); PEG 2.83 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($82.64)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. BNP Paribas Exane Downgrades Newmont Corporation (NEM) to Neutral from Outperform**
- Source: Yahoo Finance | 20251208T235200 | Neutral | Relevance: 99%
-  BNP Paribas Exane downgraded Newmont Corporation (NEM) to Neutral from Outperform, setting a $97 price target, citing increasing momentum in the copper sector and a shift towards aluminum while maintaining a constructive view on gold. Conversely, UBS analysts reiterated Buy ratings on NEM, with price targets of A$190.00 and $125 respectively, anticipating continued gold demand fueled by central banks and investors through 2026. Newmont reported strong Q3 2025 results, including record free cash flow, and announced commercial production at its Ahafo North project in Ghana, expected to contribute significantly to gold output.

**2. Jefferies Adjusts Price Target on Newmont to $120 From $113, Maintains Buy Rating**
- Source: marketscreener.com | 20251208T122231 | Somewhat-Bullish | Relevance: 98%
-  Jefferies has increased its price target for Newmont Corporation (NEM) shares to $120 from $113, while reiterating a Buy rating on the stock. This adjustment comes amidst other analyst activities, with Macquarie upgrading Newmont to Outperform and BNP Paribas Exane downgrading it to Neutral, reflecting varying perspectives on the gold mining giant. Newmont (NEM) is a leading gold mine exploration and operation company, also producing copper, silver, zinc, and lead.

**3. BNP Paribas Exane Downgrades Newmont Corporation (NEM) to Neutral from Outperform**
- Source: Finviz | 20251208T235200 | Neutral | Relevance: 98%
-  BNP Paribas Exane downgraded Newmont Corporation (NEM) to Neutral from Outperform on December 5, setting a target price of $97, citing momentum in the copper sector for 2026 and shifting preferences in gold. This contrasts with recent Buy ratings and higher price targets from UBS analysts. Newmont reported strong Q3 2025 performance with record free cash flow and achieved commercial production at its Ahafo North project.

**4. BNP Paribas Exane Downgrades Newmont Corporation (NEM) to Neutral from Outperform**
- Source: Insider Monkey | 20251208T235200 | Neutral | Relevance: 97%
-  BNP Paribas Exane downgraded Newmont Corporation (NEM) to Neutral from Outperform, setting a price target of $97, citing the copper sector's momentum and a preference switch towards aluminum and away from gold, despite continued demand for gold in 2026. This downgrade contrasts with recent Buy ratings and raised price targets from UBS analysts. Newmont reported strong Q3 2025 performance with record free cash flow and the commercial production of its Ahafo North project in Ghana.

**5. Zacks.com featured highlights include Kohl's, Heritage Insurance, Pediatrix and Newmont**
- Source: Yahoo Finance | 20251208T100836 | Bullish | Relevance: 91%
- This article highlights four stocks—Kohl's (KSS), Heritage Insurance (HRTG), Pediatrix Medical Group (MD), and Newmont (NEM)—that are trading near their 52-week highs and are expected to continue their upward momentum. The analysis, based on a momentum investing strategy, suggests these stocks have strong fundamentals, consistent performance, and positive analyst outlooks, making them attractive opportunities for investors. The article emphasizes that not all stocks at 52-week highs are overvalued and that key financial metrics and strategic developments support continued growth for these companies.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-01 | UBS | $125 | $106 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-01 | UBS | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($2.91M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (-1.1%)
- Blackrock Inc.: 11.2% (+3.4%)
- State Street Corpora: 4.5% (-0.3%)
- Geode Capital Manage: 2.4% (+3.9%)
- Van Eck Associates C: 2.2% (-42.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.83 signals overvaluation risk, limited margin of safety. Forward P/E 11.9x attractive for 20% earnings growth. Quality metrics strong (ROE 23%, ROA 10%, margin 33%). Balance sheet: strong liquidity (2.0x), $1.6B free cash flow. Analyst sentiment positive (1 raises, avg +18%). Insider selling cluster ($2.9M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $97.8B |
| Beta | 0.43 |
| 52W Range | $36.86 - $98.58 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.83 |
| Forward P/E | 11.9 |
| Current P/E | 14.2 |
| YoY Growth | 19.8% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 0.9% to -1.5% (-2.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.5pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 53.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.49% (CS: 40) | Neutral |
| RSI_14 | 53.0 | Neutral |
| MACD Histogram | 0.13 | Bullish |
| vs SMA20 | 1.005x | Above |
| vs SMA50 | 1.024x | Above |
| vs SMA200 | 1.356x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $89.00
- **Stop Loss:** $82.64 (7.1% risk)
- **Target:** $95.36 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 78
- **Position Value:** $6,942.00
- **Portfolio %:** 6.94%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-19 (Est: $1.80)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.44 | $1.71 | +18.8% |
| 2025Q2 | $1.16 | $1.43 | +22.9% |
| 2025Q1 | $0.91 | $1.25 | +37.1% |
| 2024Q4 | $1.03 | $1.40 | +35.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*